Emerging treatment options for extraintestinal manifestations in IBD

被引:77
作者
Greuter, Thomas [2 ,3 ]
Rieder, Florian [4 ]
Kucharzik, Torsten [5 ]
Peyrin-Biroulet, Laurent [6 ]
Schoepfer, Alain M. [7 ,8 ]
Rubin, David T. [9 ]
Vavricka, Stephan R. [1 ,2 ]
机构
[1] Gastroenterol & Hepatol Ctr, Zurich, Switzerland
[2] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland
[3] GZO Zurich Reg Hlth Ctr, Dept Internal Med, Wetzikon, Switzerland
[4] Cleveland Clin, Digest Dis & Surg Inst, Div Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA
[5] Klinikum Lueneburg, Div Gastroenterol & Hepatol, Luneburg, Germany
[6] Univ Henri Poincare 1, Univ Hosp Nancy, Dept Hepatogastroenterol, Inserm U954, Vandoeuvre Les Nancy, France
[7] Univ Hosp Lausanne CHUV, Div Gastroenterol & Hepatol, Lausanne, Switzerland
[8] Univ Lausanne, Lausanne, Switzerland
[9] Univ Chicago, Ctr Inflammatory Bowel Dis, Chicago, IL 60637 USA
基金
瑞士国家科学基金会;
关键词
arthritis; IBD clinical; TNF;
D O I
10.1136/gutjnl-2020-322129
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Extraintestinal manifestations (EIMs) are frequently observed in IBDs and contribute considerably to morbidity and mortality. They have long been considered a difficult to treat entity due to limited therapy options, but the increasing use of anti-tumour necrosis factors has dramatically changed the therapeutic approach to EIM in recent years. Newly emerging therapies such as JAK inhibitors and anti-interleukin 12/23 will further shape the available armamentarium. Clinicians dealing with EIMs in everyday IBD practice may be puzzled by the numerous available biological agents and small molecules, their efficacy for EIMs and their potential off-label indications. Current guidelines on EIMs in IBD do not include treatment algorithms to help practitioners in the treatment decision-making process. Herein, we summarise knowledge on emerging biological treatment options and small molecules for EIMs, highlight current research gaps, provide therapeutic algorithms for EIM management and shed light on future strategies in the context of IBD-related EIMs.
引用
收藏
页码:796 / 802
页数:7
相关论文
共 86 条
[1]   Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease [J].
Argueelles-Arias, F. ;
Castro-Laria, L. ;
Lobaton, T. ;
Aguas-Peris, M. ;
Rojas-Feria, M. ;
Barreiro-de Acosta, M. ;
Soto-Escribano, P. ;
Calvo-Moya, M. ;
Ginard-Vicens, D. ;
Chaparro-Sanchez, M. ;
Hernandez-Duran, M. ;
Castro-Senosiain, B. ;
Fernandez-Villaverde, A. ;
Garcia-Sanchez, V. ;
Dominguez-Munoz, E. ;
Caunedo-Alvarez, A. ;
Herrerias-Gutierrez, J. M. .
DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (10) :2949-2954
[2]   Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial [J].
Bachelez, Herve ;
van de Kerkhof, Peter C. M. ;
Strohal, Robert ;
Kubanov, Alexey ;
Valenzuela, Fernando ;
Lee, Joo-Heung ;
Yakusevich, Vladimir ;
Chimenti, Sergio ;
Papacharalambous, Jocelyne ;
Proulx, James ;
Gupta, Pankaj ;
Tan, Huaming ;
Tawadrous, Margaret ;
Valdez, Hernan ;
Wolk, Robert .
LANCET, 2015, 386 (9993) :552-561
[3]  
Barreiro-de-Acosta M, 2012, REV ESP ENFERM DIG, V104, P468, DOI 10.4321/s1130-01082012000900004
[4]  
Bernstein CN, 2001, AM J GASTROENTEROL, V96, P1116
[5]   The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study [J].
Bernstein, CN ;
Wajda, A ;
Blanchard, JF .
GASTROENTEROLOGY, 2005, 129 (03) :827-836
[6]   Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial [J].
Brooklyn, TN ;
Dunnill, MGS ;
Shetty, A ;
Bowden, JJ ;
Williams, JDL ;
Griffiths, CEM ;
Forbes, A ;
Greenwood, R ;
Probert, CS .
GUT, 2006, 55 (04) :505-509
[7]   Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark [J].
Burisch, Johan ;
Jess, Tine ;
Egeberg, Alexander .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (13) :2704-+
[8]   Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial [J].
Burmester, Gerd R. ;
Blanco, Ricardo ;
Charles-Schoeman, Christina ;
Wollenhaupt, Juergen ;
Zerbini, Cristiano ;
Benda, Birgitta ;
Gruben, David ;
Wallenstein, Gene ;
Krishnaswami, Sriram ;
Zwillich, Samuel H. ;
Koncz, Tamas ;
Soma, Koshika ;
Bradley, John ;
Mebus, Charles .
LANCET, 2013, 381 (9865) :451-460
[9]   Infliximab for Inflammatory Bowel Disease in Denmark 1999-2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality [J].
Caspersen, Sarah ;
Elkjaer, Margarita ;
Riis, Lene ;
Pedersen, Natalia ;
Mortensen, Christian ;
Jess, Tine ;
Sarto, Pernille ;
Hansen, Tanja S. ;
Wewer, Vibeke ;
Bendtsen, Flemming ;
Moesgaard, Flemming ;
Munkholm, Pia .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (11) :1212-1217
[10]   Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review [J].
Chateau, Thomas ;
Bonovas, Stefanos ;
Le Berre, Catherine ;
Mathieu, Nicolas ;
Danese, Silvio ;
Peyrin-Biroulet, Laurent .
JOURNAL OF CROHNS & COLITIS, 2019, 13 (12) :1569-1577